...
首页> 外文期刊>Autoimmunity reviews >Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies
【24h】

Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies

机译:SARS-COV-2感染的转录景观拆除病毒激活的致病途径,提出了独特的性别特异性差异,并预测量身定制的治疗策略

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. The present study identified a specific set of biological pathways altered in primary human lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic was studied. The transcriptomic profiles were also exploited as possible novel therapeutic targets, and anti-signature perturbation analysis predicted potential drugs to control disease progression. Among them, Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors emerged as candidate drugs. Finally, sex-specific differences that may underlie the higher COVID-19 mortality in men are proposed.
机译:严重急性呼吸综合征冠状病毒2(SARS-COV-2)疾病的出现(Covid-19)对全球健康构成严重威胁。由于没有具体的治疗方法可用于控制疾病演化,更深入地了解SARS-COV-2引起的致病机制将有助于为Covid-19的管理表征新目标。本研究确定了在SARS-COV-2感染时在原发性人肺上皮中改变的一种特定的生物途径,研究了与2003年大流行的SARS-COV的比较。转录组谱也被利用,作为可能的新疗法靶标,抗签名扰动分析预测潜在的药物来控制疾病进展。其中,丝裂原激活的蛋白激酶激酶(MEK),丝氨酸 - 苏氨酸激酶(AKT),哺乳动物催盲蛋白(MTOR)和I Kappa B激酶(IKK)抑制剂作为候选药物出现。最后,提出了可能提出的性别特异性差异,这些差异是男性较高的Covid-19死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号